Sivia Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sivia Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$339K	Sell	5,929 -12,491	-68%	-$684K	0.04%	435
2026 Q1	$1.04M	Buy	18,420 +4,932	+37%	+$288K	0.2%	130
2025 Q4	$802K	Buy	13,488 +5,986	+80%	+$326K	0.16%	162
2025 Q3	$406K	Buy	7,502 +3,063	+69%	+$175K	0.11%	234
2025 Q2	$244K	Buy	4,439 +1,102	+33%	+$64.9K	0.08%	354
2025 Q1	$236K	Buy	+3,337	New	+$224K	0.11%	212

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sivia Capital Partners's BMRN Position: Q2 2026 in Review

Sivia Capital Partners reduced its BioMarin Pharmaceuticals (BMRN) stake by 68% in Q2 2026, selling an estimated $684K and leaving 5,929 shares worth $339K. The position accounts for 0.04% of the portfolio, ranked #435.

Sivia Capital Partners first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.04M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Sivia Capital Partners held 5,929 shares of BioMarin Pharmaceuticals worth $339K as of Q2 2026.
Sivia Capital Partners sold 12,491 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $684K.
BioMarin Pharmaceuticals made up 0.04% of Sivia Capital Partners's portfolio in Q2 2026, its #435 holding.
Sivia Capital Partners first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Sivia Capital Partners's BioMarin Pharmaceuticals position peaked at $1.04M in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sivia Capital Partners's 13F filing for Q2 2026, filed 23 Jul 2026.